The mTOR Sabbatical — Rapamycin + Acarbose + Berberine Protocol
A two-tier longevity protocol centred on pulsed mTOR inhibition. Foundation Tier: weekly rapamycin with daily NMN and spermidine for autophagy support. Advanced Tier adds acarbose (postprandial glucose control) and berberine (AMPK activation) for three-pathway mTOR inhibition. The ITP showed rapamycin + acarbose produced 28% median lifespan extension in mice. Requires physician prescription and monitoring.
Daily Schedule
Timing and dosage for each step
Monday 08:00 AM
5 mg
Foundation Tier. Once weekly rapamycin. Take with a small amount of fat (improves absorption). Note the day — same day each week, every week.
Daily 08:00 AM
500 mg
Foundation Tier. NMN 500mg daily. Rapamycin's mTOR inhibition reduces NAD+ consumption — NMN maintains NAD+ levels throughout the week.
Daily 08:00 AM
1 mg
Foundation Tier. Spermidine 1mg daily (from supplement or wheat germ). Synergistic autophagy induction via independent mTOR-independent pathway.
With meals
50 mg
Advanced Tier. Acarbose 25–50mg with first bite of carbohydrate meals, up to 3x daily. Reduces postprandial glucose spikes and indirectly inhibits mTOR via insulin pathway. Start at 25mg and titrate slowly — GI side effects are common.
With meals
500 mg
Advanced Tier. Berberine 500mg 3x daily with meals, split dosing for bioavailability. Activates AMPK — the cellular energy sensor that directly inhibits mTOR.
Protocol Overview
The mTOR Sabbatical protocol centres on pulsed pharmacological mTOR inhibition — the most evidence-backed single pharmacological intervention for lifespan extension across multiple organisms.
The weekly pulse strategy (5mg once weekly) achieves mTORC1 inhibition during and for several days after dosing, while allowing mTORC2 recovery in the intervening days. This preserves the longevity benefits of mTOR inhibition while avoiding the continuous immunosuppression of transplant-dose protocols.
Foundation Tier
The core three-compound stack for mTOR inhibition and autophagy support.
Rapamycin (5mg weekly) directly inhibits mTORC1 by binding FKBP12, preventing downstream signalling through S6K1 and 4E-BP1. This is the primary mTOR inhibitor with the strongest longevity evidence — the ITP programme demonstrated 9–23% median lifespan extension in mice across multiple cohorts.
NMN (500mg daily) maintains NAD+ levels. Rapamycin's mTOR inhibition reduces NAD+ consumption — NMN ensures adequate NAD+ substrate throughout the week for cellular energy metabolism.
Spermidine (1mg daily) induces autophagy via an mTOR-independent pathway, providing additive autophagy stimulation complementary to rapamycin's mechanism.
Advanced Tier
Once the Foundation Tier is established (8+ weeks) and physician monitoring confirms good tolerance, add these two compounds for three-pathway mTOR inhibition.
Acarbose inhibits intestinal alpha-glucosidases, reducing postprandial glucose spikes and chronically lowering insulin signalling. Since insulin is a primary mTOR activator via PI3K/Akt, acarbose provides indirect mTOR inhibition through glycaemic modulation. The ITP demonstrated 22% lifespan extension in male mice — comparable to rapamycin through a complementary mechanism.
Berberine activates AMPK (the cellular energy sensor that directly inhibits mTOR) and has demonstrated comparable glucose-lowering efficacy to metformin in head-to-head trials. AMPK activation is the most physiological mTOR inhibition pathway.
The Evidence Basis
The Interventions Testing Programme (ITP) found rapamycin + acarbose produced 28% median lifespan extension in genetically heterogeneous mice — among the strongest results in mammalian longevity research. The combination appears to work via additive mechanisms: rapamycin inhibits mTORC1 directly; acarbose reduces postprandial glucose and insulin, blunting nutrient-sensing activation of mTOR.
Dosing Summary
| Compound | Dose | Timing | Notes | Tier |
|---|---|---|---|---|
| Rapamycin | 5mg | Once weekly with fatty meal | Same day each week | Foundation |
| NMN | 500mg | Daily, morning | Oral | Foundation |
| Spermidine | 1mg | Daily, morning | Supplement or wheat germ | Foundation |
| Acarbose | 25–50mg | With first bite of carb meals, up to 3x/day | Start low, titrate slowly | Advanced |
| Berberine | 500mg | 3x daily with meals | Split dosing for bioavailability | Advanced |
Cycle (Advanced Tier): 8 weeks on, 4 weeks off. The off-cycle maintains mTOR sensitivity and reduces immunosuppression concerns.
Physician Requirement
Rapamycin is a prescription medication. This protocol requires:
- Initial blood panel: fasting glucose, HbA1c, lipid panel, CBC, metabolic panel
- Prescription from a longevity-focused physician
- Regular monitoring: trough rapamycin levels (target 3–8 ng/ml), lipid panel quarterly
- Dental assessment: mouth sores are the most common side effect
Absolute contraindications for rapamycin: Active infection, immunocompromised state, live vaccine schedule, planned surgery within 3 months.
Starting Protocol
Months 1–2: 1mg/week — assess tolerance Months 3–4: 3mg/week — standard low dose Months 5+: 5mg/week — standard longevity dose Advanced (physician-guided): Up to 10mg/week + Acarbose/Berberine
What to Monitor
- Rapamycin trough level (24h post-dose): target 3–8 ng/ml
- Fasting glucose and HbA1c: quarterly
- Lipid panel (LDL, triglycerides): quarterly — rapamycin can elevate triglycerides
- CBC: every 8 weeks (check rapamycin-related effects on platelets/lymphocytes)
- Immune function: Any unusual infections warrant dose reduction
- Wound healing: Pause 2–3 weeks before elective surgery
Supporting Interventions
- Metformin 500mg (with physician guidance): additive AMPK/mTOR pathway effects
- Resistance training 3x/week: preserves muscle during mTOR inhibition
- High protein intake (1.6–2g/kg): counteracts potential lean mass effects
Disclaimer
Rapamycin is a prescription immunosuppressant. Acarbose is a prescription medication. Off-label use for longevity carries risks. This protocol is for educational purposes only and must be implemented under physician supervision.